Healthcare provider profile · identity verified

Mark E Dibbet, MD

Family Practice · ROSCOMMON, MI · NPI 1215953948

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	294	95
Losartan Potassium	Losartan Potassium	283	87
Rosuvastatin Calcium	Rosuvastatin Calcium	256	75
Atorvastatin Calcium	Atorvastatin Calcium	228	75
Metoprolol Succinate	Metoprolol Succinate	212	63
Lisinopril	Lisinopril	204	62
Levothyroxine Sodium	Levothyroxine Sodium	183	48
Metformin Hcl	Metformin Hcl	173	51
Omeprazole	Omeprazole	173	59
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	155	35
Hydrochlorothiazide	Hydrochlorothiazide	128	42
Gabapentin	Gabapentin	127	46
Sertraline Hcl	Sertraline Hcl	110	34
Tamsulosin Hcl	Tamsulosin Hcl	107	34
Pravastatin Sodium	Pravastatin Sodium	100	31
Pantoprazole Sodium	Pantoprazole Sodium	94	28
Simvastatin	Simvastatin	89	23
Albuterol Sulfate Hfa	Albuterol Sulfate	87	46
Eliquis	Apixaban	81	29
Tramadol Hcl	Tramadol Hcl	81	27
Furosemide	Furosemide	75	21
Metoprolol Tartrate	Metoprolol Tartrate	71	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	68	suppressed
Fluticasone Propionate	Fluticasone Propionate	67	33
Potassium Chloride	Potassium Chloride	64	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	62	22
Glimepiride	Glimepiride	62	19
Fluoxetine Hcl	Fluoxetine Hcl	60	15
Allopurinol	Allopurinol	58	18
Duloxetine Hcl	Duloxetine Hcl	57	23
Carvedilol	Carvedilol	54	17
Alprazolam	Alprazolam	53	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	13
Prednisone	Prednisone	47	24
Alendronate Sodium	Alendronate Sodium	46	15
Ezetimibe	Ezetimibe	46	17
Atenolol	Atenolol	43	13
Famotidine	Famotidine	42	17
Trulicity	Dulaglutide	42	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Warfarin Sodium	Warfarin Sodium	41	12
Doxycycline Hyclate	Doxycycline Hyclate	40	34
Lovastatin	Lovastatin	40	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	38	24
Celecoxib	Celecoxib	37	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	suppressed
Trazodone Hcl	Trazodone Hcl	37	11
Finasteride	Finasteride	35	suppressed
Nitroglycerin	Nitroglycerin	34	23
Xarelto	Rivaroxaban	34	suppressed
Carbamazepine	Carbamazepine	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Morphine Sulfate Er	Morphine Sulfate	25	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Lorazepam	Lorazepam	24	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	24	suppressed
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Cephalexin	Cephalexin	21	17
Chlorthalidone	Chlorthalidone	21	suppressed
Glipizide Er	Glipizide	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	20	suppressed
Bumetanide	Bumetanide	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Clonazepam	Clonazepam	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Meloxicam	Meloxicam	19	suppressed
Ramipril	Ramipril	19	suppressed
Fenofibrate	Fenofibrate,micronized	18	suppressed
Topiramate	Topiramate	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Diazepam	Diazepam	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Glipizide	Glipizide	15	suppressed
Modafinil	Modafinil	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Risedronate Sodium	Risedronate Sodium	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Azithromycin	Azithromycin	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Estradiol	Estradiol	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	11
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Digoxin	Digoxin	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Trimethoprim	Trimethoprim	12	suppressed
Dutasteride	Dutasteride	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Nystatin	Nystatin	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error